Business Wire

Juniper Networks Chosen to Upgrade Virgin Media O2’s Core IP Backbone Network to 800G Readiness

23.1.2023 11:00:00 EET | Business Wire | Press release

Share

Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Virgin Media O2, one of the UK’s largest fixed and mobile service providers with approximately 50 million online media connections, successfully upgraded its IP core backbone network with Juniper – capable of supporting 800G. Virgin Media O2 is investing in sustainable infrastructure for the long term that can support sustained data growth and bandwidth demands. Its investment underpins the rapid introduction of revenue-generating services while delivering significantly-reduced power, cooling and space consumption and costs.

Consistently good user experience is a fundamental benchmark of success. As its 5G and network expansion continues, Virgin Media O2 turned to Juniper to build a network that is 400G-enabled and 800G-ready to create a near future-proofed digital foundation for its customers. Virgin Media O2 selected Juniper as the technology partner for this strategic upgrade for numerous reasons, including its previous track record as a key networking provider for more than ten years with Virgin Media and O2 before their joint venture in 2021. Another significant factor was Juniper’s ability to deliver compelling economics for Virgin Media O2. These include long-term investment protection through continuous custom silicon innovation by keeping pace with market demands, the planned use of automation tools to help reduce operational costs and a favorable Total Cost of Ownership (TCO) with a reduced energy consumption design.

News Highlights

  • In the past year, Virgin Media O2 has seen 32 percent traffic growth on its mobile network, 16 percent growth in broadband data downloads and a peak traffic load of 22TB, underlining the need for increased data capacity and flexible scalability
  • Virgin Media O2 has successfully migrated all core traffic in its six backbone locations across the UK with Juniper Networks PTX10008 Packet Transport Routers, which are purpose-built to deliver cloud-optimized network transformation at scale and with operational flexibility
  • The modular PTX10008 routers deliver reduced resource consumption as a result of inherently-sustainable design features, including front-to-back cooling, flexible power supplies that can use either high- or low-power modes and high-density port capability that enables optimized throughput in a compact form factor
  • Scalable, secure 400G capability is achieved through ultra-high port density, native inline MACSec encryption on all ports, coupled with the latest generation of ASIC innovation that powers a range of line cards
  • PTX10008 routers support 400G coherent optical transceivers (400G ZR and ZR+) without any density loss today, and are 800G-capable with upgradeability to 800G in the future with silicon innovation and easily-exchanged line cards in the chassis
  • Virgin Media O2’s infrastructure will be underpinned by Juniper’s single operating system, Junos® OS Evolved. This will provide ongoing continuity for streamlined operations.

Supporting Quotes

“Virgin Media O2’s stated ambition is to ‘upgrade the UK’, providing fast, seamless broadband access and mobile services to as many homes and businesses as possible. This calls for responsible, strategic innovation and investment to create an agile network infrastructure that can simultaneously scale in step with our business, be mindful of resource consumption and deliver an extended lifecycle that protects our investment. Juniper is a long-standing technology partner, so it is very reassuring that it has the same vision for sustainable growth, user experience and the fundamental importance of digital enablement in our communities and economy.”

- Jeanie York, Chief Technology Officer, Virgin Media O2

“Service providers face a complex set of technical and commercial challenges that can be contradictory, even intractable—and likely only to multiply in the future—without the right approach. Virgin Media O2 has chosen to leverage silicon, software and automation innovation from Juniper that can turn complexity on its head to deliver a simplified, more reliable and more sustainable network foundation for its business. This means the company can embrace and accelerate growth and service evolution, safe in the knowledge that its millions of users will continue to be able to enjoy the best digital experiences going forward, whatever demands the future may bring.”

- Raj Yavatkar, Chief Technology Officer, Juniper Networks

Additional Information

Juniper’s Climate Change & Sustainability Pages
CEO Blog: Juniper’s Carbon Neutral Pledge
CTO Blog: Sustainable Networking – The Time is Now
Juniper’s 2022 Corporate Sustainability Report

About Juniper Networks

Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

Statement of Product Direction

The information on this page may contain Juniper's development and plans for future products, features, or enhancements ("SOPD Information"). SOPD Information is subject to change at any time, without notice. Juniper provides no assurances, and assumes no responsibility, that future products, features, or enhancements will be introduced. In no event should any purchase decision be based upon reliance of timeframes or specifics outlined as part of SOPD Information, because Juniper may delay or never introduce the future products, features, or enhancements.

Any SOPD Information within, or referenced or obtained from, this website by any person does not give rise to any reliance claim, or any estoppel, against Juniper in connection with, or arising out of, any representations set forth in the SOPD Information. Juniper is not liable for any loss or damage (howsoever incurred) by any person in connection with, or arising out of, any representations set forth in the SOPD Information.

Category - Cloud & Service Provider

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations:
Penny Still
Juniper Networks
+44 (0) 1372 385 692
pstill@juniper.net

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye